• Johnson & Johnson (NYSE:JNJ) anticipates fourth-quarter earnings per share to shrink to $2.02, down from $2.29.
• Projected revenue is expected to rise to $22.45 billion, indicating a positive sales trajectory.
• The FDA’s recent approval of Spravato nasal spray may enhance future sales prospects.

Johnson & Johnson (NYSE:JNJ) is a renowned global healthcare corporation with a diverse portfolio encompassing pharmaceuticals, medical devices, and consumer health products. On January 22, 2025, Johnson Rice updated its rating for JNJ to Neutral, opting for a hold recommendation given that the stock price was around $148.15. This update comes ahead of the company’s fourth-quarter earnings announcement.

Analysts predict Johnson & Johnson will report earnings at $2.02 per share for the fourth quarter, reflecting a decrease compared to $2.29 per share incurred during the same period last year. Despite this decline in earnings, revenue is expected to improve to $22.45 billion, up from $21.39 billion a year prior, signaling a positive trend in overall sales performance.

A recent milestone for Johnson & Johnson is the FDA’s approval of the Spravato nasal spray for broader usage. This approval positions the spray as a treatment option for adult patients with major depressive disorder who have not responded to two or more traditional oral antidepressants. This FDA milestone has the potential to significantly bolster Johnson & Johnson’s psychiatric product offerings.

Prior to the earnings release, JNJ shares saw a modest increase of 0.8%, closing at $148.15. The stock has experienced an 8.88% decline over the past year, yet it has rebounded by 2.79% year-to-date. This recent price increase reflects growing investor optimism surrounding the company’s impending earnings announcement and recent regulatory success.

Johnson & Johnson currently boasts a market capitalization close to $356.69 billion, with a trading volume of 8,262,191 shares. Today, the stock witnessed fluctuations between a low of $147.05 and a high of $148.85. Over the past year, JNJ recorded a high of $168.85 and a low of $140.68, illustrating volatility in its stock activity.